8-K: Sangamo Therapeutics Prioritizes Neurology Pipeline, Reports Full Year 2023 Results

Sangamo Therapeutics announced its full year 2023 financial results and highlighted advancements in its neurology pipeline, including promising preclinical data for its novel AAV capsid delivery technology.

Summary

• Sangamo Therapeutics reported a net loss of $257.8 million for the full year 2023, compared to a net loss of $192.3 million in 2022.
• The company's revenue increased to $176.2 million in 2023 from $111.3 million in 2022, primarily due to the termination of the Biogen collaboration agreement.
• Operating expenses for 2023 totaled $450.2 million, including significant impairment charges, compared to $312.6 million in 2022.
• Sangamo is prioritizing its neurology pipeline, focusing on epigenetic regulation therapies and novel AAV capsid delivery technology.
• Preclinical data for the STAC-BBB capsid showed industry-leading blood-brain barrier penetration and potent gene repression in non-human primates.
• The company expects IND submissions for chronic neuropathic pain in the fourth quarter of 2024 and a CTA submission for prion disease in the fourth quarter of 2025.
• Sangamo has aligned with the FDA on an abbreviated pathway for its Fabry disease program and received PRIME eligibility from the EMA.
• Pfizer anticipates BLA and MAA submissions for their Hemophilia A collaboration by early 2025, pending supportive pivotal data.
• Sangamo's cash, cash equivalents, and marketable securities were $81.0 million as of December 31, 2023, and they expect this to fund operations into the third quarter of 2024.
• The company is actively seeking additional capital and collaboration partners.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive advancements in the pipeline and technology, the significant financial losses, limited cash runway, and restructuring efforts temper the overall sentiment. The need for additional funding and partnerships introduces uncertainty.

Positives

• The STAC-BBB capsid shows industry-leading blood-brain barrier penetration and gene expression in neurons.
• Preclinical data supports the advancement of programs for chronic neuropathic pain, prion disease, and tauopathies.
• The FDA alignment on an abbreviated pathway for Fabry disease could accelerate approval and reduce costs.
• EMA PRIME eligibility for Fabry disease treatment aims to expedite the review and approval process.
• The Hemophilia A program with Pfizer is progressing towards potential BLA and MAA submissions in early 2025.
• The company is actively seeking partnerships and additional funding to support its programs.
• The restructuring of operations is expected to reduce operating expenses.

Negatives

• Sangamo reported a significant net loss of $257.8 million for 2023.
• The company's cash reserves have decreased significantly to $81.0 million.
• The company expects its current cash reserves to only fund operations into the third quarter of 2024.
• The company is winding down its French operations, resulting in job losses.
• The company has experienced a decrease in revenue from collaboration agreements with Kite and Novartis.
• The company has incurred significant impairment charges related to goodwill and long-lived assets.

Risks

• Sangamo's lack of capital resources may hinder its ability to fully develop and commercialize its product candidates.
• The company's ability to secure additional funding or partnerships is uncertain.
• Clinical trial results may not be indicative of results in future trials.
• The regulatory approval process for product candidates is unpredictable.
• The company is reliant on collaborators and may be unable to secure additional collaborations.
• Macroeconomic factors and financial challenges could impact the company's operations and collaborations.
• The company's restructuring efforts may have unintended consequences.

Future Outlook

Sangamo expects to advance its neurology pipeline, seek partnerships for its Fabry disease and CAR-Treg programs, and secure additional funding to support its operations. The company anticipates several key milestones in the coming years, including IND and CTA submissions for its preclinical programs and potential regulatory submissions for its partnered programs.

Management Comments

• In 2023, Sangamo announced the prioritization of its pipeline programs that support our focus as a neurology-focused genomic medicine company, said Sandy Macrae, Chief Executive Officer of Sangamo.
• With the meaningful preclinical data announced today, we believe our ability to combine potent zinc finger epigenetic regulation payloads with exciting new industry-leading capsid delivery technology could unlock significant potential for the treatment of devastating neurological diseases, indications for which delivery of treatments to the central nervous system has historically proved challenging.
• In the near-term, we are also seeking to create value by partnering our Fabry disease program, for which we aligned with the FDA on a potentially abbreviated and more cost-effective timeline and received EMA PRIME eligibility.

Industry Context

Sangamo's focus on neurology and its novel AAV capsid technology positions it in a competitive space within the gene therapy sector. The company's efforts to address diseases with high unmet medical needs, such as prion disease and tauopathies, align with broader industry trends in developing innovative treatments for neurological disorders. The partnerships with Pfizer and the pursuit of collaborations for other programs reflect a common strategy in the biotech industry to share development costs and expertise.

Comparison to Industry Standards

• Sangamo's STAC-BBB capsid demonstrates a 700-fold increase in transgene expression compared to AAV9, a commonly used benchmark in gene therapy, suggesting a significant advancement in delivery technology.
• The company's focus on epigenetic regulation using zinc finger technology is a differentiated approach compared to traditional gene editing methods like CRISPR, which are being pursued by companies such as CRISPR Therapeutics and Editas Medicine.
• The alignment with the FDA on an abbreviated pathway for Fabry disease is similar to strategies employed by other companies seeking accelerated approvals for rare disease treatments, such as BioMarin Pharmaceutical.
• The partnership with Pfizer for Hemophilia A is comparable to other large pharmaceutical companies collaborating with smaller biotech firms to develop gene therapies, such as Roche's partnership with Spark Therapeutics.
• Sangamo's financial situation, with a significant net loss and limited cash runway, is not uncommon for biotech companies in the clinical development stage, but it highlights the need for successful fundraising or partnerships, similar to challenges faced by companies like bluebird bio.

Stakeholder Impact

• Shareholders are impacted by the significant net loss and the need for additional funding, which could lead to dilution.
• Employees are affected by the restructuring, including the wind down of French operations and associated job losses.
• Patients with neurological diseases may benefit from the potential development of new therapies.
• Collaborators, such as Pfizer, are impacted by the progress of partnered programs and the potential for future milestones and royalties.
• Creditors are impacted by the company's financial situation and its ability to meet its obligations.

Next Steps

• Sangamo plans to participate in several investor conferences in May and June 2024.
• The company expects to complete dosing in the Phase 1/2 STAAR study in the first half of 2024.
• The company plans to continue seeking a potential collaboration partner or external investment in its CAR-Treg cell therapy programs.
• The company expects IND submissions for chronic neuropathic pain in the fourth quarter of 2024.
• The company expects a CTA submission for prion disease in the fourth quarter of 2025.
• The company intends to resume development of its tau program, with a potential IND submission as early as the fourth quarter of 2025.

Key Dates

Keywords

neurology, gene therapy, AAV capsid, blood-brain barrier, epigenetic regulation, prion disease, tauopathies, Fabry disease, hemophilia A, clinical trials, IND, CTA, FDA, EMA, financial results, restructuring